The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–Guerin

Peer review under responsibility of Arab Association of Urology.

Figures & data

Fig. 1 (A) A case of T1G2, showing a strong nuclear reaction to p53; ×400. (B): A case of T1G2, showing a weak nuclear reaction to p63; ×400.

Fig. 2 (A) A case of T1G2, showing a strong membranous reaction to her2/neu; ×100. (B): A case of T1G3, showing a strong membranous reaction to her2/neu; ×200.

Table 1 Clinical patient data in relation to the immunohistochemical profile of p53, p63, and her2.

Variable (n)	p53		p63		Her2/neu
	+/–	P	+/–	P	+/–	P
Tumour stage
High risk (44)	24/20	NS	12/32	0.005	26/18	0.010
(Ta/T1 G3, Cis)
Intermediate risk (44)	20/24		22/22		24/20
(Ta/T1 G1/G2)
Grade (n)
G1/G2 (64)	35/29	0.010	42/22	0.025	30/34	0.025
G3 (24)	20/4		8/16		18/6
Cytology before BCG
Positive (45)	10/35	NS	12/33	NS	23/22	NS
Suspicious (23)	–/–		–/–		–/–
Negative (20)	–/–		–/–		–/–
Multifocal tumours
Yes (56)	30/26	NS	23/33	NS	37/19	NS
No (32)	15/17		14/18		12/20
Associated Cis
Yes (46)	38/8	NS	11/35	NS	30/16	NS
No (42)	22/20		19/23		20/22
Recurrence
<6 months (15)	12/3	<0.01	3/12	<0.025	10/5	<0.05
>6 months (12)	8/4		8/4		3/9
Progression
Yes (12)	6/6	<0.01	3/9	0.005	7/5	0.025
No (76)	26/50		28/48		28/48
Death
Yes (3)	2/1	0.010	0/3	0.010	2/1	0.005
No (85)	52/33		51/34		29/56

Table 2 Patients with progression; stage, grade and immunohistochemical profile for p53, p63 and her2.

Patient	Stage before BCG	p53	P63	Her2	Progression	Death (month)
1	T1 G3	+ve	−ve	+ve	T2G3	30
2	Ta G3	+ve	+ve	+ve	T1G2	–
3	Ta G3	−ve	+ve	+ve	T2G2	–
4	T1 G3	+ve	+ve	+ve	T2G3	–
5	Ta G2	+ve	−ve	−ve	T1G3?	32
6	T1 G2	−ve	−ve	−ve	T3G2	–
7	T1 G3	−ve	−ve	+ve	T3G3	–
8	T1 G2	−ve	−ve	−ve	T2G3	–
9	T1 G2	+ve	−ve	−ve	T3G2	–
10	T1 G2	−ve	−ve	−ve	T3G3	–
11	Ta G3	+ve	−ve	+ve	T2G3	–
12	T1 G1	−ve	−ve	+ve	T3G3	20